Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut.
Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, New York.
Am J Perinatol. 2023 Oct;40(13):1390-1397. doi: 10.1055/a-2096-5199. Epub 2023 Sep 18.
This study aimed to investigate whether aspirin 81 mg daily for preeclampsia prevention is associated with increased risk of postpartum blood loss at the time of delivery.
This is a retrospective cohort study performed at a tertiary hospital from January 2018 to April 2021. Data were extracted from the electronic medical record. Patients prescribed low-dose aspirin (LDA) were compared with patients who were not. The primary outcome was a composite of postpartum blood loss, defined as: estimated blood loss (EBL) >1,000 mL, documentation of International Classification of Diseases-9/-10 codes for postpartum hemorrhage (PPH), or red blood cell (RBC) transfusion. Bivariate analysis, and unadjusted and adjusted logistic regression modeling were performed.
Among 16,980 deliveries, 1,922 (11.3%) were prescribed LDA. Patients prescribed LDA were more likely to be >35 years old, nulliparous, obese, taking other anticoagulants, or have diagnoses of diabetes, systemic lupus erythematosus, fibroids, or hypertensive disease of pregnancy. After adjusting for potential confounders, the significant association between LDA use and the composite did not persist (adjusted odds ratio [aOR]: 1.1, 95% confidence interval [CI]: 1.0-1.3) nor did the association between EBL > 1,000 mL (aOR: 1.0, 95% CI: 0.9-1.3) and RBC transfusion (aOR: 1.3, 95% CI: 0.9-1.7). The association between LDA and PPH remained significant (aOR: 1.3, 95% CI: 1.1-1.6). Patients who discontinued LDA <7 days prior to delivery had an increased risk of the postpartum blood loss composite compared discontinuation ≥7 days (15.0 vs. 9.3%; = 0.03).
There may be an association between LDA use and increased risk of postpartum bleeding. This suggests that use of LDA outside the recommended guidelines should be cautioned and further investigation is needed to determine its ideal dosing and timing of discontinuation.
· There may be an association with LDA and an increased risk of postpartum bleeding.. · Patients who discontinued LDA less than 7 days prior to delivery had an increased rate of postpartum bleeding.. · Additional research is need to determine optimal LDA dose and timing of discontinuation..
本研究旨在探讨每日服用 81 毫克阿司匹林预防子痫前期是否会增加分娩时产后出血的风险。
这是一项在 2018 年 1 月至 2021 年 4 月期间在一家三级医院进行的回顾性队列研究。数据从电子病历中提取。将服用低剂量阿司匹林(LDA)的患者与未服用的患者进行比较。主要结局是产后出血的复合结局,定义为:估计失血量(EBL)>1000 毫升,国际疾病分类第 9 或 10 版(ICD-9/10)产后出血(PPH)代码的记录,或红细胞(RBC)输注。进行了双变量分析、未调整和调整后的逻辑回归模型。
在 16980 例分娩中,有 1922 例(11.3%)开具了 LDA。服用 LDA 的患者更可能年龄>35 岁、初产妇、肥胖、服用其他抗凝药物,或患有糖尿病、系统性红斑狼疮、肌瘤或妊娠高血压疾病。在调整了潜在混杂因素后,LDA 使用与复合结局之间的显著关联不再存在(调整后的优势比[aOR]:1.1,95%置信区间[CI]:1.0-1.3),EBL>1000 毫升(aOR:1.0,95%CI:0.9-1.3)和 RBC 输注(aOR:1.3,95%CI:0.9-1.7)也不存在关联。LDA 与 PPH 之间的关联仍然显著(aOR:1.3,95%CI:1.1-1.6)。与停药≥7 天相比,停药<7 天的患者产后出血复合结局的风险增加(15.0% vs. 9.3%; = 0.03)。
LDA 使用与产后出血风险增加之间可能存在关联。这表明,应谨慎使用超出推荐指南的 LDA,并需要进一步研究以确定其理想的剂量和停药时间。
·LDA 与产后出血风险增加之间可能存在关联。·停药<7 天的患者产后出血发生率增加。·需要进一步研究确定 LDA 的最佳剂量和停药时间。